Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Prostate cancer
Stage/Subtype:  stage IV prostate cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 150 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: Adult
Sponsor: NCI, Other
Protocol IDs: CDR0000064184, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, PR8, NCT00002651
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: Other
Protocol IDs: 05-043, NCT00116142
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: N0574, NCCTG-N0574, ACOSOG-N0574, CDR0000499633, NCI-2009-00653, NCT00377156
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 128308, NCI-2009-01530, P30CA016056, RPCI-I-128308, NCT00887432
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0924, CDR0000701128, NCI-2011-02674, NCT01368588
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1216, SWOG-S1216, NCI-2012-02876, NCT01809691
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A031201, U10CA031946, NCI-2013-01737, NCT01949337
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SP005, 2012-002814-38, NCT02111577
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR105505, 56021927PCR3001, NCT02257736
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ANZUP 1304, ACTRN12614000110684, NCT02446405
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ANZUP1303, ACTRN12614000126617, NCT02446444
Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 424Sm32, NCT00121095
Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I 68905, RPCI-I-68905, NCT00536991
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PH&S IRB 10-088, NCT01303705
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APC-100-01, NCT01436214
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IM-T-IMMU-132-01, NCT01631552
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12-120, NCT01688492
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13P.128, 2013-02, NCT01848067
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140015, 14-C-0015, NCT01989546
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: IRB13-0979, NCI-2013-02151, CDMRP-PC121149, P30CA014599, NCT02012296
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ADXS142-03, NCT02325557
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASN001-101, NCT02349139
Start Over